MDSCs are a heterogenous population of immature myeloid cells that expands and negatively regulates immune responses during cancer progression, inflammation, and infection. 11 Since they lack the expression of lineage markers specific for B, T cells, natural killer (NK) cells, or macrophages, they were not originally classified and thus were called "null" cells. [11] [12] [13] MDSCs promote tumor evasion by inhibiting T-cell response and inducing other immunosuppressive cells such as Tregs, mechanisms of which may involve depletion of essential amino acids from the tumor microenvironment required for T cell proliferation; alternatively, they may involve oxidative stress by generating NO and reactive oxygen species (ROS) that inhibit T cell recruitment; and finally, they may produce anti-inflammatory cytokines such as TGF-b and IL-10 amongst other immunosuppressive factors. [11] [12] [13] [14] Additionally, MDSCs can directly promote tumor proliferation, metastasis, and angiogenesis through non-immunological mechanisms. 12, 15, 16 MicroRNAs are small non-coding RNAs of approximately 18-24 nucleotides in length in their mature form that is involved in post-transcriptional regulation of gene expression. The physiological and pathological roles of miRNAs in immune system regulation have been widely studied. 17 Particularly, multiple miRNAs have been implicated in the expansion, activation, and functional regulation of MDSCs in the tumor microenvironment. 8, 10, 18, 19 Nevertheless, the mechanisms by which tumors deliver miRNAs to MDSCs in the microenvironment, and the means by which these tumor-derived miRNAs modulate MDSCs growth and activity, are largely unknown. Previous studies showed that TDEs could be taken up by MDSCs and that molecular cargos delivered by TDEs were capable of promoting accumulation and activation of MDSCs, which consequently enhanced tumor progression. 8, 10 Whether MDSC-modulating miRNAs could be delivered via TDEs, and how these exogenous miRNAs regulate the expansion and function of MDSCs, remained to be determined.
In this study, we show that miR-107, one of the highly expressed miRNAs in gastric cancers, 20, 21 is able to be transferred from tumor cells to HLA-DR − CD33 + MDSCs via gastric cancer-secreted TDEs, where it targets DICER1 and PTEN genes to promote expansion and activity of MDSCs. Furthermore, miR-107-enriched TDEs, when given to mice intravenously, are able to induce accumulation of CD11b + Gr1 +/high MDSCs in the peripheral blood. Together, these findings provide evidence of how tumor cells modulate the immunosuppressive microenvironment by secreting miRNA-enriched TDEs, and identify a novel mechanism by which tumor-derived miR-107 promotes MDSCs accumulation and activity, hence suggesting the targeting of tumor-derived miR-107 as an approach to block the cross-talk between cancer cells and host MDSCs to inhibit tumor growth and augment immunotherapy efficacy.
Methods

Animals, cell lines and reagents
All animal studies were conducted in accordance with Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC) guidelines with the approval of the Institutional Animal Care and Use Committee of Drug Safety Evaluation Center of the First Affiliated Hospital of Henan University of Chinese Medicine (protocol number YFYDW2015013). BALB/c mice (~20 g, female) were provided by the Laboratory Animal Center of Zhengzhou University (License number: 41003100002475), and maintained under an SPF (Specific Pathogen Free) level of care. The human gastric cancer cell lines MGC-803, BGC-823, SGC-7901, and gastric epithelial cell line GES-1 were purchased from the Shanghai Cell Bank of Chinese Academy of Sciences, and cultured in RPMI-1640 complete medium (Solarbi Co., Beijing, China), containing 10% fetal bovine serum (FBS) (Hyclone), 10 ng/mL rhGM-CSF (R&D Systems, Inc., Minneapolis, MN, USA). Human embryonic kidney cell line HEK293T was purchased from Shanghai Cell Bank of Chinese Academy of Sciences, and cultured in DMEM complete medium containing 10% FBS (Solarbi Co.).
Exosome isolation and transmission electron microscopy
The study was conducted in accordance with the Declaration of Helsinki, and all subjects gave written informed consent to participate. The Ethics Committee of the First Affiliated Hospital of Henan University of Chinese Medicine approved the study (protocol number 2016HL-085). Serum was separated from the peripheral blood, aliquoted (150 μl/tube) and frozen at −80°C. Exosomes (TDEs) were then isolated using the PureExo® Exosome Isolation kit for serum or plasma (101bio, california, USA) according to the manufacturer's instructions. To obtain exosomes secreted by gastric cancer cells, human gastric cancer cell lines MGC-803, BGC-823 and SGC-7901 were serum-starved for 48 hrs, and the culture media were then collected for exosome extraction using the PureExo® Exosome Isolation kit for cell culture media (101bio).
To quality control the isolated exosomes, a JEM-1400 transmission electron microscope (TEM) (JEOL Inc., Peabody, MA, USA) was used to observe the morphologies and sizes of the exosomes. The exosomes were prepared using the Exosome Preparation kit for transmission electron microscopy (101bio) according to the manufacturer's instructions. The protein contents of exosomes were analyzed by a BCA protein assay kit (SigmaAldrich Co., St Louis, MO, USA). The exosomes were also labeled with CD9 and CD63 antibodies (Abgent, San Diego, CA, USA) and analyzed by western blot.
MDSCs isolation and culture
To obtain peripheral blood nucleated cells, FACS hemolysing solution (BD Biosciences, San Jose, CA, USA) (diluted 1:10 with deionized water) was added into EDTA-treated human whole blood. The mixture was then incubated at room temperature for 10 min, centrifuged at 20°C for 5 min, washed twice with PBS to remove red blood cells. MDSCs were maintained in vitro in RPMI-1640 complete medium supplemented with 2 mM L-glutamine, 10 mM HEPES, 20 mM 2-ME, 10% fetal bovine serum, penicillin/streptomycin, and 40 ng/ml hGM-CSF, at 37°C in a humidified 5% CO 2 incubator. 
HLA-DR
Flow cytometry and antibodies
For flow cytometry a BD FACSCanto II flow cytometer and FACSDiva TM analysis were used. The following antibodies were purchased from BD Biosciences: anti-HLA-DR-PE-Cy 7, anti-CD33-APC, anti-CD11b-APC-Cy7, anti-CD14-PerCP -Cy5.5, anti-CD15-PE-Cy7 and anti-ARG-1-FITC; and their corresponding isotype negative control antibodies: mouse IgM-PE-Cy7, mouse IgG1-APC, rat IgG2b APC-Cy7, mouse IgG2a-PerCP-Cy5.5, and mouse IgM-PE-Cy7.
Detecting intracellular ARG1 in MDSCs subgroups by flow cytometry
Immune cells in peripheral blood were labeled with anti-HLA-DR-PE and anti-CD33-APC fluorescent antibody. The mixture was then centrifuged at 1500 rpm for 15 mins at 18°C and the supernatant was discarded. The pellet was then mixed with 100 μl of cytomembrane punching reagent 1 (Beckman Coulter, Brea, CA, USA), which was mixed gently, and incubated for 15 mins without light at 25°C. Cells were then washed with normal saline (NS) and centrifuged at 1500 rpm for 5 mins. The supernatant was then discarded and the pellet mixed with 100 μl of cytomembrane punching reagent 2. This was incubated for 5 mins without light at 25°C. Then, 5 μl of ARG1-FITC was added and incubated for 15 mins without light at 25°C. Next, 1ml of was added and the mixture centrifuged at 1500 rpm for 5 mins. The supernatant was then discarded and the labelled cells resuspended in 500 μl of FCM buffer solution for detection.
Mature miRNA and pre-miRNA purification and real-time quantitative PCR
To extract miRNAs from cultured cells and serum, a NucleoSpin® miRNA column (Macherey-Nagel GmbH & Co. KG, Duren, Germany) was used. To extract exosomal miRNAs and pre-miRNAs, a SeraMir Exosome RNA purification kit (Systems Biology Institute, Tokyo, Japan) was used following manufacturer's instructions.
miRNA real-time quantitative PCR (RT-qPCR) was performed using miRACLE PCR Primers and a miRACLE RT-qPCR Detection Kit (both from Genetimes Technology Inc., Shanghai, People's Republic of China). For ARG1, DICER1, PTEN, PI3K, AKT, mTOR, and NFkB mRNAs, the SYBR Green RT-PCR kit (TaKaRa Bio Inc., Kusatsu, Japan) was used instead. Primers for detecting all mRNAs are included in Table S1 . All qPCR reactions were run on an ABI 7,500 system (Applied Biosystems, California, USA), and analyzed using the 2 −△△Ct method.
miRNA target gene luciferase reporter assay and knockdown
To generate pmiR-RB-Report™-hDICER1 and pmiR-RBReport™-hPTEN dual luciferase reporter plasmids, 3ʹUTRs of DICER1 and PTEN were PCR-amplified using HEK293T genomic DNA as a template and cloned into the pmiR-RB-REPORT™ dual luciferase reporter vector (RiuboBio Co. Ltd., Guangzhou, China.). To generate reporter plasmids with mutated miR-107 binding sequences, site-directed mutagenesis was performed to mutate "ATGCTGC" to "TACGACG" on hDICER1 3ʹUTRs, and "ATGCTGC" to "TACGACG" on PTEN 3ʹUTR. To validate the target genes of hsa-miR-107, HEK293T cells were co-transfected with hsamiR-107 mimic (50 nM), together with pmiR-RB-Report™-hDICER1 or pmiR-RB-Report™-hPTEN plasmids (1 μg) 
miRNA-107 overexpression and knockdown
To determine the effect of has-miR-107 overexpression or knockdown on MDSC proliferation, HLA-DR 
Western blot analysis
To extract total proteins, HLA-DR − CD33 + MDSCs were lysed by RIPA solution containing 50 mM Tris-HCl (pH7.4), 1%(v/ v) Triton X-100, 1 mM EDTA, 1 mM leupeptin, 1 mM phenylmethylsulfonyl fluoride, 10 mM NaF, and 1 mM Na3VO4, and then centrifuged at 13,000 g for 15 min at 4°C. The protein quantity was determined by a BCA protein kit (SigmaAldrich Co.). Total protein lysate of 60 μg was separated by SDS-polyacrylamide gel (SDS-PAGE) electrophoresis and transferred to a polyvinylidene fluoride (PVDF) membrane. The PVDF membrane was then incubated with one of the following primary antibodies overnight at 4°C: anti-DICER1, anti-PTEN, anti-ARG1, anti-NOS2, Anti-AKT, anti-mTOR, anti-NF-kB, anti-p-AKT (ser473), anti-p-mTOR (ser2448), anti-p65-NF-kB (ser536) (1:1000 dilution), and anti-β-actin (1:5000) antibodies. Membranes were then incubated with HRP-conjugated goat anti-mouse IgG secondary antibody (diluted 1:2000) for 2 hrs at room temperature (all antibodies were from Santa Cruz Biotechnology, California, USA), followed by a standard chemiluminescent detection procedure. Image J software was used to determine relative protein expression quantitatively. 
Ethics approval and consent to participate
Statistical analysis
All experiments were performed in triplicate and repeated in at least 3 independent studies. The data were presented as mean ± SD from at least three independent experiments. Student's t-test was used for all comparisons and P<0.05 was considered statistically significant.
Results miR-107 expression was elevated in gastric cancer cells, their secreted exosomes, and serum of gastric cancer patients Previous studies showed that miR-107, among other miRNAs, was up-regulated in gastric cancer tissues, and its expression was correlated with disease prognosis, tumor invasion, and metastasis. [20] [21] [22] However, whether miR-107
is over-represented in TDEs secreted by gastric cancer cells has remained elusive. TDEs were isolated from MGC-803, BGC-823, SGC-7901 gastric cancer cell lines, GES-1 normal gastric epithelial cell line, and serum samples. We examined the morphologies and sizes of the exosomes under a transmission electron microscope, JEM-1400. The sizes of these TDEs ranged from 30 to 100 nm in diameter ( Figure 1A ). In addition, we found enriched expression of exosomal surface markers CD9 and CD63 in isolated exosomes from gastric cell line and serum samples ( Figure 1B ). To determine miR-107 expression, we performed RTqPCR on total RNAs extracted from MGC-803, BGC-823, SGC-7901, and GES-1 cell lines. As shown in Figure 1C -a, miR-107 expression was 2-4 fold higher in gastric cells than that of the normal GES-1 cells (P<0.01). This result corroborates previous findings that gastric cancer cells have elevated expression of miR-107. [20] [21] [22] More importantly, we found that miR-107 content in TDEs derived from these 3 gastric cancer cell lines was 3-5 fold higher than in exosomes from GES-1 cells (P<0.01) ( Figure 1C exosomes isolated from the peripheral blood of gastric cancer patients, we performed miR-107 RT-qPCR on miRNAs extracted from the serum of cancer patients and healthy volunteers. We found that miR-107 expression was significantly higher in the serum of gastric cancer patients than those of healthy subjects (P<0.01) ( Figure 1D ). In summary, our data shows that miR-107 was not only overexpressed in gastric cancer cell lines, but also over-represented in the TDEs secreted by these cells as well as in those found in the peripheral blood of gastric cancer patients.
Gastric cancer cells can deliver miR-107 into HLA-DR -CD33 + MDSCs via TDEs in vitro
To determine whether miR-107 in the gastric cancer cellderived TDEs could be delivered into HLA-DR − CD33 + MDSCs, we transfected the gastric cancer cell line SGC-7901 with a Cy3-conjugated miR-107. We extracted TDEs as described in the Materials and Methods. We then incubated HLA-DR − CD33 + MDSCs with the TDEs for 6
hrs before examining for Cy3 expression. As shown in Figure 2A -D, in vitro incubation with the TDEs was sufficient to deliver Cy3-labled miR-107 into MDSCs.
To determine the amount of miR-107 delivered into
MDSCs via TDEs, we incubated HLA-DR − CD33 + MDSCs with the TDEs for 24 hrs before examining for miR-107 expression by RT-qPCR. As shown in Figure 2E , incubation with gastric cancer cell-derived TDEs increased miR-107 expression by more than 4 fold as compared with that in the unincubated MDSCs (P<0.01). To exclude the possibility that the increased miR-107 expression was due to upregulation of the endogenous miR-107 gene in the MDSCs, we measured the level of precursor miR-107 (pre-miR-107) by RT-qPCR. We found that, unlike mature miR-107, there was no significant difference in pre-miR-107 expression (fold change =1.14; P>0.05) between unincubated MDSCs and MDSCs exposed to miR-107-containing TDEs ( Figure 2E ), suggesting that the increased miR-107 in MDSCs was from the exogenous gastric cancer cellderived TDEs.
miR-107 targets 3ʹUTRs's of DICER1 and PTEN mRNAs in a "seed" sequence-specific manner sequence to that within, in most cases, the 3ʹUTRs of the target mRNA. 23 In order to confirm that DICER1 and PTEN could be targeted by miR-107, we performed TargetScan, 24 PicTar, 25 and miRanda 26 (microrna.org and miRBase) to search for potential miR-107-binding sequences ("seed" sequence: UACGACGA) within the 3ʹUTRs of these 2 genes. Six possible binding sites were found in the DICER1 mRNA-3ʹUTR ( Figure 3A ) and two possible binding sites were found in the PTEN mRNA-3ʹUTR ( Figure 3B ). To verify target engagement of miR-107 to the 3ʹUTRs of DICER1 and PTEN mRNAs, we generated 2 luciferase reporter plasmids, pmiR-RB-Report™-hDICER1 and pmiR-RB-Report™-hPTEN, and transfected them into HEK293T cells together with a miR-107 mimic. We found that the miR-107 mimic was capable of interfering with luciferase reporter expression in the presence of intact miR-107 "seed" binding sequences within the 3ʹUTR of either DICER1 (P<0.05) ( Figure 3C ) or PTEN (P<0.05) ( Figure 3D ) mRNAs. However, decreased reporter expression was not found in the cells transfected with mutant miR-107 binding sequences, nor in cells without miR-107 mimic ( Figure 3C and D). Taken together, these data demonstrate that miR-107 is able to target the 3ʹUTRs of both DICER1 and PTEN mRNA's and these interactions are highly dependent upon the presence of intact sequences in the 3ʹUTRs complementary to the "seed" sequence of mature miR-107.
Exosomal miR-107 derived from gastric cancer cells down-regulates DICER1 and PTEN expression in MDSCs by miR-107, we performed gain-and loss-of-function studies in which we transiently transfected synthetic miR-107 mimics, miR-107 inhibitors (anti-miR) and an unrelated control miRNA into the MDSCs and determined their effects on DICER1 and PTEN expression. As shown in Figure 4A , the miR-107 mimic increased expression of miR-107 up to 9 fold (P<0.01) compared with that in cells transfected with control miRNA, while the anti-miR decreased miR-107 expression around 40%. Notably, neither miR-107 mimic nor inhibitor significantly changed the target gene expression at the mRNA level as determined by RTqPCR (P>0.05) ( Figure 4B ). On the other hand, miR-107 mimic reduced while the inhibitor increased expression of both DICER1 and PTEN at the protein level (P<0.05) ( Figure 4C-D) . (P<0.05) (Figure 4F-G Figure 5D ). On the contrary, HLA-DR − CD33 + MDSCs with miR-107 low TDEs were significantly decreased compared to the control group (P<0.05) ( Figure 5D ). These data suggest that miR-107 derived from SGC-7901 TDEs can induce the proliferation of HLA-DR − CD33 + MDSCs.
We showed that miR-107 suppressed DICER1 expression by targeting its mRNA 3ʹUTR (Figure 3C) , and that exosomal miR-107 was able to induce MDSCs expansion ( Figure 5D ). To determine whether the effect of miR-107 on MDSCs proliferation was dependent upon its ability to target the DICER1 mRNA 3ʹUTR, we separately transfected WT and mutant DICER1- To determine the effect of exogenous miR-107 on ARG1 expression in HLA-DR − CD33 + MDSCs in vitro, we separately transfected miR-107 mimic, inhibitor and a control miRNA into MDSCs, and verified their effects on miR-107 expression by RT-qPCR (fold change >3; P<0.05) ( Figure 6A ). We found that MDSCs transfected with the miR-107 mimic showed a significant increase in Figure 6B ). Furthermore, we confirmed the expression of ARG1 at the protein level by flow cytometry. As shown in Figure 6C and D, miR-107 mimic increased ARG1 protein expression in HLA-DR − CD33 + MDSCs (fold change >3; P<0.05), while the effect was absent in MDSCs transfected with either the anti-miR or unrelated control miRNA. We next sought to determine whether miR-107 derived from SGC-7901 TDEs had the same effect on ARG1 expression in MDSCs. We generated miR-107 high and miR-107 low TDEs and co-incubated with HLA-DR − CD33 + MDSCs before measuring miR-107 and ARG1 expression by RTqPCR. As shown in Figure 6E , miR-107 expression was significantly higher in miR-107 high TDE-co-incubated cells (fold change >3; P<0.05), while those with miR- 4032 low TDEs showed lower miR-107 expression compared to that of the control group. In addition, expression of ARG1 mRNA was increased in MDSCs co-incubated with miR-107 high TDEs (fold change >4; P<0.01) ( Figure   6F ), as well as ARG1 protein as determined by flow cytometry (fold change >3; P<0.01) ( Figure 6G and H). These data support that miR-107 in gastric cancer cellderived exosomes is capable of increasing ARG1 expression in HLA-DR − CD33 + MDSCs.
miR-107 induces ARG1 expression in MDSCs by inhibiting PTEN
We demonstrated that miR-107 could target the 3ʹUTR of PTEN mRNA to decrease its expression ( Figure 3D ), and that exosomal miR-107 was able to induce ARG1 expression ( Figure 6 ). To determine whether the effect of miR-107-promoted ARG1 expression was dependent upon its ability to target the PTEN mRNA 3ʹUTR, we co-transfected miRNA-107 mimic with WT or mutant PTEN-3ʹUTR plasmid into Figure 7A ). Additionally, we found expression of both ARG1 mRNA (fold change >3.0; P<0.05) ( Figure 7B ) and protein (P<0.05) ( Figure 7C ) significantly increased in cells co-transfected with miR-107 mimic and WT but not mutant PTEN-3ʹUTR. Since PTEN is one of the most important negative regulators of the PI3K pathway, it is therefore of interest to determine whether miR-107-induced PTEN suppression has an impact on PI3K pathway activation and if this change leads to induction of ARG1 expression as observed in miR-107-transfected MDSCs. As shown in Figure 7D , MDSCs co-transfected with miR-107 mimic and WT PTEN-3ʹUTR showed increased mRNA expression of PI3K, AKT, mTOR, and NFkB, as compared to the expression in MDSCs without transfected miR-107 mimic (P<0.05); whereas miR-107 mimic failed to induce expression of the 4 mRNAs when in the presence of a mutant PTEN-3ʹUTR. Furthermore, cotransfection with miR-107 mimic and WT PTEN-3ʹUTR not only induced protein expression of PI3K, AKT, mTOR, and NF-kB, but also increased phosphorylated AKT (p-AKT), p-mTOR and the NF-kB subunit p65 (P<0.05) ( Figure 7E  and F PTEN and ARG1 after 96 hrs in culture. As shown in Figure  7G and H, PTEN-targeting siRNA decreased PTEN protein expression compared to that of scrambled siRNA. Also, MDSCs transfected with PTEN siRNA also showed decreased expression of ARG1 both in mRNA ( Figure 7I ) and protein ( Figure 7J and K) levels. Importantly, PTEN knockdown by siRNA in MDSCs also led to activation of the PI3K pathway, which was implicated by increased mRNA expression of its downstream effectors AKT, mTOR, and NF-kB ( Figure 7L ), as well as AKT, mTOR, NF-kB, p-AKT, p-mTOR proteins ( Figure 7M and N) . In summary, we show that miR-107 is able to suppress PTEN expression via targeting its mRNA 3ʹUTRs, which leads to activation of the PI3K pathway, and MDSCs using MACS separation. The MDSCs were also labeled with CFSE proliferation dye (green fluorescent). As shown in Figure 8A -C, we observed co-localization of CFSE dye and Cy3-labeled miR-107 mimic in almost all the isolated mouse MDSCs, suggesting SGC-7901 TDEs can deliver the mimic into MDSCs in vivo. We then asked whether miR-107 delivered by the TDEs can induce MDSCs expansion in the animals. For this purpose, TDEs from parental SGC-7901 cells (SGC-7901-EXO) or those transfected with miR-107 inhibitor (INH-EXO) were isolated, and injected into tail veins of mice with a bolus of 20 μg exosomes every other day for 7 times. Also included in the study were exosomes from healthy volunteer serums (HDS-EXO) and TDEs from gastric cancer patient serums (PS-EXO), the latter of which were shown to contain miR-107 TDEs ( Figure  1D ). Seventy-two hrs after the last dose, whole blood was withdrawn from the abdominal vein of mice, and the percentage of CD11b
MDSCs was analyzed by flow cytometry using FITC anti-Gr-1 and PE anti-CD11b antibodies. We found a significantly higher percentage of CD11b
MDSCs, but not CD11b
−/low cells, in mice injected with SGC-7901 TDEs or cancer patient TDEs than that in animals injected with miR-107-depleted TDEs or healthy donor exosomes ( Figure 8D and E), demonstrating that miR-107 delivered via gastric cancer TDEs is able to induce expansion of MDSCs in vivo.
We showed that exosomal miR-107 from gastric cancer cells is capable of suppressing DICER1 and PTEN and inducing ARG1 in isolated MDSCs in vitro. We then asked whether expression of DICER1, PTEN, ARG1, and NOS2 in CD11b
MDSCs can also be modulated by exosomal miR-107 in vivo. Thus, we isolated CD11b
MDSCs by MACS sorting from animals injected with SGC-7901-EXO, INH-EXO, PS-EXO, HDS-EXO, and saline negative control (NS), and determined expression of DICER1, PTEN, ARG1, and NOS2 genes by RT-qPCR and Western blot. We found significantly lower expression of ARG1 and NOS2, while expression of DICER1 and PTEN was higher in MDSCs from mice injected with either SGC-7901-EXO or PS-EXO (P<0.05), but not with INH-EXO, HDS-EXO, or NS ( Figure 8F ). We saw the same effects in protein levels for these genes (P<0.05) ( Figure 8G and H). These data suggest that miR-107 delivered via gastric cancer TDEs to mouse CD11b + Gr1 +/high MDSCs is able to induce ARG1
and NOS2 and suppress DICER1 and PTEN gene expression in vivo, validating our in vitro observations in cultured HLA-DR − CD33 + MDSCs.
Discussion
The major focus of oncology drug development in past decades has been to identify cancer-specific targets and to develop novel therapeutic strategies to efficiently eliminate cancer cells while sparing their normal counterparts. While these efforts resulted in a number of promising treatments, the efficacy was generally limited by intrinsic clonal heterogeneity and the presence of complex tumor microenvironments, 27 27 Previous studies showed that miR-107 was overexpressed in gastric cancers and its expression was associated with a poor prognosis in gastric cancer patients; 20 furthermore, miR-107 was shown to regulate gastric cancer cell invasion and metastasis by targeting the DICER1 gene. 21 Our findings, however, reveal a previously unknown mechanism by which miR-107 contributes to tumorigenesis. We show that in addition to regulating local gene expression in cancer cells, miR-107 is also able to be transmitted to bone marrow-derived immune cells in the tumor microenvironment to support cancer immune escape. Interestingly, we found that miR-107 delivered via TDEs is also capable of modulating expression of the DICER1 gene in HLA-DR − CD33 + MDSCs, much like it does in gastric cancer cells. 21 DICER1, an RNase III endoribonuclease that is involved in the cleavage and maturation of miRNAs from pre-miRNAs, plays a key role in global miRNA biogenesis. 38 It has been shown that impairment of miRNA maturation enhanced transformation in cancer cells, and that global down-regulation of miRNAs was functionally relevant to oncogenesis; therefore, it was not surprising that DICER1 was identified as a tumor suppressor in human cancers, 21, 39, 40 and that miR-107-mediated DICER1 down-regulation resulted in tumor progression. 21 On the other hand, the role of DICER1 suppression in MDSCs within the tumor microenvironment was relatively undefined. Nevertheless, several transgenic animal studies showed that DICER1 deletion results in de-repression of stem cell self-renewal genes in myeloid-committed progenitor cells, abnormal myeloid differentiation, and myeloid dysplasia, a precancerous growth of myeloid cells. 41 Our data shows that exogenous miR-107 from gastric cancer-derived TDEs suppresses DICER1 expression, leading to expansion of MDSCs, implicating that in pathological conditions, DICER1 could also promote myeloid cell proliferation and survival. Furthermore, the horizontal transfer of miR-107 from gastric cancer cells to MDSCs suggests that the level of miR-107 would not be affected by global loss of miRNA biogenesis caused by DICER1 down-regulation, by passing a potential feedback regulatory mechanism between miR-107 and DICER1.
42
While the role of PTEN in tumor suppression is well documented, 43, 44 its importance in other disease such as diabetes, infectious diseases, inflammation and neurodevelopmental disorders, has been relatively less studied. 45, 46 Apparently, in the context of infectious diseases such as pneumococcal pneumonia, PTEN blockade results in the dampening of inflammation in the lung and prolonging of animal survival post-bacterial infection. 46 To elucidate the molecular mechanisms of PTEN-mediated anti-inflammatory responses, researchers exposed PTEN-deficient myeloid cells to pathogens and searched for genes that were differentially expressed as compared to those in wild-type myeloid cells, and found that loss of PTEN, or activation of PI3K signaling, led to decreased expression of multiple pro-inflammatory cytokines. 47 In the same study, ARG1 was also identified as one of the differentially expressed genes in the PTENdeficient myeloid cells; ARG1 expression was markedly induced by PTEN deletion in macrophages, leading to a hypo-inflammatory environment. 48 ARG1, a key player in the urea cycle, converts arginine to urea; therefore, myeloid cell-derived ARG1 is capable of depleting arginine from the environment under inflammatory conditions. As a result, a shortage of arginine blocks proliferation of T cells leading to T cell anergy and prevents T helper cell functions. 49, 50 Like myeloid cells undergoing an inflammatory response, MDSCs within the tumor microenvironment are also capable of suppressing immune responses via a series of inhibitory mechanisms, which contributes to tumor growth. Studies showed that tumor cell-derived prostaglandin E2 (PGE2) induced upregulation of ARG1 in MDSCs, and ultimately led to cell cycle arrest in T cells. 12, 51 However, unlike that under inflammatory conditions, the connection between PTEN regulation and ARG1 expression has not been well defined for MDSCs within the tumor microenvironment. In this study, we demonstrated that gastric cancer cell-derived miR-107 could suppress MDSCs, which led to markedly increased ARG1 expression and immune suppression. These findings also raise further questions as to whether regulation of ARG1 expression in MDSCs is controlled by multiple complementary or redundant mechanisms (such as PTEN and PGE2-mediated regulation), and whether other PTEN-targeting miRNAs (such as miR-21, miR181b, and miR-494) also contribute to ARG1 expression in MDSCs. 19 Nonetheless, we showed that siRNA targeting PTEN increased ARG1 expression in MDSCs more than 4 fold as compared to that of control siRNAtreated cells, suggesting that the ARG1 level was directly modulated by PTEN status in the MDSCs ( Figure 7I-K) . Undoubtedly, the tumor microenvironment is one of the indispensable components for tumor growth and survival, and inside it there are a large number of tumorsecreted molecules that contribute to the development of cancerous growth. Being able to stably transfer their molecular cargos to target cells, exosomes have been proven to be an effective and efficient intercellular communication vehicle between cancer cells and other cells in the tumor microenvironment. 52 Our study provides evidences that gastric cancer-secreted TDEs can carry miR-107 and deliver it into HLA-DR − CD33 + MDSCs to promote host immunosuppression that facilitates tumor progression.
Conclusion
In summary, our findings demonstrate for the first time that gastric cancer-secreted exosomes are able to deliver miR-107 to the host MDSCs, meanwhile we found that by suppressing both DICER1 and PTEN genes in MDSCs, gastric cancerderived miR-107 was able to promote MDSCs expansion as well as induce its immunosuppressive function via increasing ARG1 expression. These findings not only broaden our understanding of how cancer cells may mediate immune escape at a distant site from the primary tumor, but also provide useful insights into development of MDSC-targeting therapeutic agents that may dramatically increase anti-cancer immunotherapy efficacy.
Abbreviation list
ARG1, arginase 1; GC, gastric cancer; MDSCs, myeloidderived suppressor cells; NOS2, nitric oxide synthase2; PBMC, peripheral blood mononuclear cell; PTEN, phosphatase and tensin homolog; ROS, reactive oxygen species; RT-PCR, reverse transcription-polymerase chain reaction; TDEs, tumor-derived exosomes; miR, microRNA; Treg, regulatory T cells.
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